-
Sector Analysis
Hepatic Encephalopathy Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
This reports provides a data-driven overview of the current and future competitive landscape in Hepatic Encephalopathy therapeutics. • In 2024, more than 4.5 million diagnosed prevalent cases of HE are anticipated in the 16 countries covered in GlobalData’s epidemiology forecast for HE. • Currently, there is a single approved innovator drug available in the market for HE. • R&D activities for HE are moderate with 12 molecules in the pipeline, out of which Phase III holds only one drug, whereas...
-
Product Insights
Hepatic Encephalopathy - Drugs In Development, 2024
Empower your strategies with our Hepatic Encephalopathy – Drugs In Development, 2024 report and make more profitable business decisions. Hepatic encephalopathy is a worsening of brain function that occurs when the liver is no longer able to remove toxic substances in the blood. Symptoms include disorientation, drowsiness or confusion, change in sleep patterns, slurred speech and agitation, excitement, or seizures (occur rarely). The predisposing factors include gastrointestinal bleeding, increased protein intake, renal dysfunction with azotemia, constipation (due to increased nitrogen load),...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.